Loading...
•
Jun 30, 2025
Absci Q2 2025 Earnings Report
Absci reported a wider net loss in Q2 2025 amid increased R&D investment, while bolstering its financial position with a $64M raise in July.
Key Takeaways
Absci's Q2 2025 results showed ongoing execution across internal and partnered pipelines. Despite a drop in revenue and a higher net loss, the company strengthened its balance sheet, extending runway into 2028.
Q2 revenue declined to $0.6M from $1.3M YoY
Net loss widened to $30.6M driven by higher R&D spending
Raised $64M in July to support operations through H1 2028
Expanded collaboration with Almirall and progressed internal assets ABS-101 and ABS-201
Forward Guidance
Absci expects continued progress in clinical and preclinical development, further collaborations, and operational stability through 2028.
Positive Outlook
- Raised $64M in July 2025 through equity offerings
- Cash runway extended into H1 2028
- ABS-101 Phase 1 interim data expected in H2 2025
- ABS-201 expected to enter Phase 1/2a in early 2026
- Ongoing platform scaling through AMD partnership
Challenges Ahead
- Revenue decreased YoY from $1.3M to $0.6M
- Net loss increased to $30.6M
- Higher R&D expenses drove greater burn
- Ongoing reliance on external funding
- Operating losses continue with no near-term profitability
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...